Reduced Immunogenicity of Intraparenchymal Delivery of Adeno-Associated Virus Serotype 2 Vectors: Brief Overview

This article will illustrate the low risk of immune response to AAV serotype 2 vector-mediated gene therapy to the brain with support from clinical trial data in aromatic L-amino acid decarboxylase deficiency and Parkinson disease.PMID:34551695 | DOI:10.2174/1566523221666210922155413
Source: Current Gene Therapy - Category: Genetics & Stem Cells Authors: Source Type: research